Physician profile
Martha E Ryan
NPI 1427443738
$2,545.61
in general payments reported to CMS, 2019-2025
9 companies · $1,153 in 2025
The $1,153 reported for 2025 was more than what 80% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $523 · 2020: $91.30 · 2021: $28.80 · 2022: $17.99 · 2023: $296 · 2024: $435 · 2025: $1,153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,000 · Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,000.00 |
| Food and Beverage | $884.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $1,145.63 | 2024-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Glaukos Corporation | $541.15 | 2019-2022 | |
| Alcon Vision LLC | $470.63 | 2023-2025 | Hydrus Microstent, Clareon |
| Sight Sciences, INC. | $127.63 | 2024 | Omni Surgical System |
| Ocular Therapeutix, INC. | $120.62 | 2023 | Dextenza |
| Aerie Pharmaceuticals, INC. | $91.30 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.85 | 2023 | |
| Omeros Corporation | $16.39 | 2021 | |
| Biotissue Holdings INC. | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martha Ryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.